ClinicalTrials.gg
Drug

Neratinib clinical trials

Also written Nerlynx and HKI-272.

studies test it
76
open now
18
in phase 3
4
first study started
2003

How each study uses neratinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the neratinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
17 Jul 2017 · NERLYNX · NDA 208051 (FDA, Drugs@FDA)
European Union
31 Aug 2018 · Nerlynx · EMEA/H/C/004030 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Neratinib
65
Neratinib Maleate
3
Neratinib + endocrine therapy
2
Neratinib tablets
2
2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-, (2Z)-2-butenedioate (1:1)
2

Brand

Nerlynx
23

Development codes

HKI-272
14
PF-05208767
1

Studies by the year they started

75 studies that test it; most in 2009 (9); 1 more planned to start later

Studies that test neratinib, by start year
YearStudies
20031
20051
20064
20073
20086
20099
20104
20111
20123
20134
20142
20152
20163
20173
20181
20192
20204
20213
20226
20234
20246
20253

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
33
Phase 2
49
Phase 3
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 36 · Other 40

Puma Biotechnology, Inc. (33) · NSABP Foundation Inc (4) · Convalife (Shanghai) Co., Ltd. (3) · Memorial Sloan Kettering Cancer Center (2) · Virginia Commonwealth University (2) · Dana-Farber Cancer Institute (2) · National Cancer Institute (NCI) (2) · University Health Network, Toronto (2)

Often tested with

Tested in the same studies.

Trastuzumab (4) · Fulvestrant (4) · Niraparib (3) · Capecitabine (3) · Loperamide (2) · Alpelisib (2) · Binimetinib (2) · Olaparib (2)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 6, 1 in phase 3

Studies that test neratinib, phase 3 first.

Studies

Open first, then newest update. How each study uses neratinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 76

See all 76 studies that test neratinib →

Given beside what is tested · 6 — neratinib is usual care or a partner of the new treatment

Codes

What other systems call neratinib · ClinicalTrials.gg INT004670

  • MeSH (NLM) C487932neratinibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) JJH94R3PWBNERATINIBConfirmed FDA, NLM, Wikidata
  • RxNorm 1940643Confirmed FDA, Wikidata
  • Wikidata Q6995920neratinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C49094NeratinibConfirmed FDA, Wikidata
  • DrugBank DB11828One source Wikidata

Also registered as neratinib maleate anhydrous (UNII 9RM7XY23ZS · RxNorm 1940642).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.